Accéder directement au contenu Accéder directement à la navigation
Nouvelle interface
Article dans une revue

Aspirin in people with diabetes: Time to clean up the prescription list?

Abstract : The effect of aspirin in primary cardiovascular (CV) prevention in people with diabetes is still a matter of debate. Recent results of ASCEND trial suggest that the absolute benefit on CV events is largely counter-balanced by the bleeding risk. However, one crucial question is whether aspirin should be maintained or withdrawn from the prescription list of those who are already under this therapy since a while ago. Indeed, large epidemiological data reported that the aspirin discontinuation was associated to an increased risk of CV events. Moreover, besides the CV outcome, potential positive impact of aspirin on cancer is still under investigation. To conclude, there is no more systematic indication for aspirin in people with diabetes free of CV disease, especially when diabetes and all other CV risk factors are optimally controlled. For those already on aspirin, data are not conclusive enough for a systematic approach and benefit/risk balance must be discussed with patients to take a shared decision.
Type de document :
Article dans une revue
Liste complète des métadonnées
Contributeur : Accord Elsevier CCSD Connectez-vous pour contacter le contributeur
Soumis le : vendredi 22 octobre 2021 - 15:21:19
Dernière modification le : samedi 26 mars 2022 - 04:24:46
Archivage à long terme le : : lundi 24 janvier 2022 - 16:57:37


Fichiers produits par l'(les) auteur(s)


Distributed under a Creative Commons Paternité - Pas d'utilisation commerciale 4.0 International License



Julien Vouillarmet, Victor Aboyans. Aspirin in people with diabetes: Time to clean up the prescription list?. Diabetes Research and Clinical Practice, 2019, ⟨10.1016/j.diabres.2019.02.005⟩. ⟨hal-02043843⟩



Consultations de la notice


Téléchargements de fichiers